Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) just unveiled an announcement.
CARsgen Therapeutics Holdings Ltd. announced the passing of Mr. Bingsen Guo, a non-executive director who had been with the company for over a decade. Mr. Guo played a crucial role in the company’s strategic transformation and development, providing key support during critical business initiatives. His contributions have been instrumental in overcoming challenges and ensuring the company’s steady growth. The board expressed its condolences to Mr. Guo’s family and acknowledged his significant impact on the company’s success.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biotechnology company focused on the development of innovative CAR-T cell therapies for the treatment of cancer. The company operates in the biopharmaceutical industry and is dedicated to advancing its pipeline of products to address unmet medical needs in the oncology market.
Average Trading Volume: 2,607,231
Technical Sentiment Signal: Hold
Current Market Cap: HK$11.68B
See more data about 2171 stock on TipRanks’ Stock Analysis page.